Overview

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM).

Phase:

Phase 1

Details

Lead Sponsor:

Tel-Aviv Sourasky Medical Center

Collaborator:

Weizmann Institute of Science

Treatments:

Cyclosporine
Cyclosporins
Dexamethasone